Viatris Inc (VTRS) stock

VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3010% below fair value

$20.82+0.15 (+0.73%)

Close on Nov 13, 2026Market cap $23.91BP/E –Yield 2.31%

Viatris EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Viatris's EV/EBITDA was 10.9× on Jan 31, 2025, against 7.9× a year earlier. Over the last 5 years it ranged from 3.1× to 16.3×, with a median of 7.5×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2025	Jan 31, 2025	10.9×	−0.6
2024	Dec 31, 2024	11.4×	+3.8
2023	Dec 29, 2023	7.6×	+0.6
2022	Dec 30, 2022	7.0×	−2.4
2021	Dec 31, 2021	9.3×	+5.4
2020	Dec 31, 2020	4.0×	+0.7
2019	Dec 31, 2019	3.3×	–

Where these numbers come from

Parsed from the XBRL in Viatris's annual and quarterly filings with the SEC
Per-share figures adjusted for the 3-for-2 split on Oct 9, 2003
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VTRS.

Compare: VTRS vs TEVA · VTRS vs GRFS · VTRS vs BHC · VTRS vs OGN · VTRS vs ZTS

Revenue growth4.3% · median -1.2%

Gross margin35.3% · median 64.4%

Operating margin-0.0% · median 11.3%

Company	Revenue	Growth
VTRS	$14.73B	+4.3%
TEVA	$14.10B	-15.2%
BHC	$11.11B	+10.8%
ZTS	$9.49B	+0.9%
OGN	$6.10B	-3.2%
GRFS	–	–

Company

Next earnings (est.): Feb 25, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 30,000
Held by institutions: 91.5%
Auditor: DELOITTE & TOUCHE LLP
SEC CIK: 1792044

Advertisement
300 × 250

See a number that looks wrong?